{"id":"W2754327139","doi":"10.1016/s0140-6736(17)32440-6","title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial","year":2017,"lang":"en","type":"article","venue":"The Lancet","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":1704,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; Ottawa Hospital; University Health Network","funders":"Janssen Biotech; National Cancer Institute; Stand Up To Cancer; EMD Serono; Genentech; ImmunoGen; Ajinomoto; Clovis Oncology; Amgen; American Association for Cancer Research; National Ovarian Cancer Coalition; Regeneron Pharmaceuticals; University College London; Cancer Research UK; Array BioPharma; Memorial Sloan-Kettering Cancer Center; Ajinomoto Pharmaceuticals; Roche; AbbVie; Merck; Ovarian Cancer Research Fund; AstraZeneca; OncoMed Pharmaceutical; Ovarian Cancer Research Fund Alliance; U.S. Department of Defense","keywords":"Medicine; Placebo; Oncology; Internal medicine; Ovarian carcinoma; Double blind; Ovarian cancer; Surgery; Cancer; Alternative medicine; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}